Erdheim-chester disease: Case report with testes involvement and review of literature

Havva Sezer a,*, Murat Serhat Aygün b, Ayşe Armutlu c, Ömer Acar d, Fikri Okan Falay e, Dilek Yazici a, Oğuzhan Deyneli a, Faruk Alagoğlu a

a Koç University School of Medicine, Division of Endocrinology and Metabolism, Turkey
b Koç University School of Medicine, Department of Radiology, Turkey
c Koç University School of Medicine, Department of Pathology, Turkey
d Koç University School of Medicine, Department of Urology, Turkey
e Koç University School of Medicine, Department of Nuclear Medicine, Turkey

Article info
Article history:
Received 17 January 2018
Received in revised form 8 February 2018
Accepted 14 February 2018
Available online 25 February 2018

Keywords:
Erdheim-chester disease
Non-Langerhans histiocytosis
Xanthogranulomatous infiltration

Introduction

Histiocytosis is a group of rare diseases characterized by abnormal accumulation of macrophages, dendritic cells or monocyte-derived cells in different tissues causing various clinical findings. ECD is a rare, non-familial, non-Langerhans cell histiocytosis of unknown etiology with characteristic radiological and histological features, which was firstly described by Jakob Erdheim and William Chester in 1930. There have been up to 700 cases reported to date. Recently ECD has been recognized as an inflammatory myeloid neoplasia associated with oncogenic mutations of kinase signaling pathway including BRAF, NRAS, KRAS, MAP2K1, and PIK3CA in histiocytes. The recent studies have demonstrated BRAFV600E mutations in more than 50% cases. It is characterized by excessive proliferation of CD68-positive and CD1a-negative foamy histiocytes and lipid-laden macrophages in different organs and tissues. The most relevant characteristics of ECD are described in Table 1. The prognosis depends on the extent and distribution of the disease, ranging from asymptomatic bone lesions to life-threatening forms. Respiratory distress, extensive pulmonary fibrosis and cardiac failure are the most common cause of death. We described here the case of a 53 year old caucasian man who presented with hypogonadism and diabetes insipidus, having a rare organ involvement of testes (see Fig. 1).
Positron emission tomography revealed increased uptake in the distal ends of the bilateral femurs and tibias, on the perivascular region of the thoracic and abdominal aorta, bilateral testes, and perirenal region. Cerebrospinal fluid was obtained to determine the etiology of the stalk infiltration and the result was unremarkable. The testis was recommended as the optimal biopsy site. A biopsy was taken from the testis tissue. A diffuse infiltration by epitheloid cells with abundant foamy cytoplasm, multinucleated cells with the appearance of touton-type giant cells and patchy lymphoid infiltrate were found. The testicular tubules were atrophied and replaced by hyaline and collagenous material. On immunohistochemical staining, the cells were positive for CD68, and negative for CD1a. These findings supported the diagnosis of ECD. BRAF mutation was not detected in heavily infiltrated testis tissue. The treatment started with interferon-alpha injections subcutaneously at the doses of 3 × 10^6 units 3 times weekly.

**Discussion**

ECD may be asymptomatic or may present as a severe multisystemic disease with life-threatening manifestations. Now, ECD is considered as a clonal hematopoietic disorder with MAPK signaling pathway genetic alteration. The skeletal involvement is the most common initial presentation. In our case there was an osteosclerotic lesion in the left distal femoral region and positron emission tomography images showed increased symmetric FDG uptake in the distal ends of the bilateral femurs and tibias, on the perivascular region of the thoracic and abdominal aorta, bilateral testes, and perirenal region. Cerebrospinal fluid was obtained to determine the etiology of the stalk infiltration and the result was unremarkable. The testis was recommended as the optimal biopsy site. A biopsy was taken from the testis tissue. A diffuse infiltration by epitheloid cells with abundant foamy cytoplasm, multinucleated cells with the appearance of touton-type giant cells and patchy lymphoid infiltrate were found. The testicular tubules were atrophied and replaced by hyaline and collagenous material. On immunohistochemical staining, the cells were positive for CD68, and negative for CD1a. These findings supported the diagnosis of ECD. BRAF mutation was not detected in heavily infiltrated testis tissue. The treatment started with interferon-alpha injections subcutaneously at the doses of 3 × 10^6 units 3 times weekly.

**Table 1**

| Characteristics of Erdheim-Chester disease. |
|---------------------------------------------|
| **Definition** | Multisystemic non-Langerhans histiocytosis of unknown origin |
| **Population** | Middle-aged patients, slight male predominance, the median age of diagnosis is 55 years (in fifth decade) with few cases reported in children |
| **Pathophysiology/ Histology** | Shows polyclonal proliferation of histiocytes associated with abnormal T1 immune response. The recent studies have suggested a clonal origin by demonstrating BRAFV600E mutations in more than 50% cases. Xanthogranulomatosis or polymorphic granuloma with foamy/lipid laden histiocytes with immunoreactivity to CD68, but negative for CD1a |
| **Most common findings** | Any tissue or organ can be affected, bone is most frequently affected (>90%), at least one soft tissue component is seen in more than 50% of patients, symptomatic or asymptomatic, bilateral, symmetric cortical osteosclerosis of the diaphyseal and metaphyseal regions of the long bones Retropertioneal involvement, associated with renal failure and/or renovascular hypertension Peri-aortic infiltration (coated aorta) Hairy kidneys Central nervous system involvement (diabetes insipititus, panhypopituitarism, headache, ataxia) Orbital, exophthalmas, diploia, visual impairment Pulmonary involvement Pericardial involvement cardiac tamponade, cardiac failure, myocardial infarction Skin, xanthelasma, xanthoma |
| **Diagnostic criteria** | Foamy histiocyte infiltration and fibrosis or xanthogranulomatosis, with positive CD68 and negative CD1a |

**Fig. 1.** Testis biopsy showed xanthogranulomatous infiltrate, mainly composed by foamy histiocytes accompanied by fibrosis with multinuclear touton-like giant cell.

Table 2

| Laboratory tests before and after the interferon alpha treatment. | 03.03.2017 (before) | 27.05.2017 (after 3 months) | 14.09.2017 (after 6 months) |
|---------------------------------------------------------------|----------------------|-----------------------------|-----------------------------|
| FSH mIU/ml | 1.5–12.4 | 12.8 | 55.9 | 65.4 |
| LH mIU/ml | 1.7–8.6 | 20.7 | 152 | 1002 |
| Total Testosterone ng/dL | 280–800 | 48.9 | 55.9 | 65.4 |
| Free Testosterone pg/mL | 7–22.7 | 2.14 | 1.1 | 1008 |
| Prolaktin ng/mL | 4.0–15.2 | 30.7 | 152 | 1002 |
| Sodium mg/dL | 1.3 | 1.1 | 1.1 | 1008 |
| Creatinine mg/dL | 1.0 | 1.1 | 1.1 | 1008 |
| Urinary Density g/dL | 130 | 410 | 410 | 410 |
| Idrar Osmolalitesi mosm/kg | 11 | 13.7 | 13.7 | 13.7 |
| ACTH microg/L | 8–25–26 | 42 | 60.6 | 60.6 |
| Cortisol ug/dL | 1.01 | 1.01 | 1.01 | 1.01 |
| Short ACTH stimulation test cortisol respond ug/dL | 1.01 | 1.01 | 1.01 | 1.01 |
| TSH ug/mL | 0.3–4.2 | 6.47 | 2.45 | 2.45 |
| FT4 ng/dL | 0.8–1.7 | 1.01 | 1.01 | 1.01 |
| FT3 pg/mL | 1.1 | 1.1 | 1.1 | 1.1 |
| Anti TPO IU/mL (<35) | 205 | 653 | 653 | 653 |
| Anti TG IU/mL (<115) | 61.6 | 79.4 | 79.4 | 79.4 |
| Sedimentation mm/h (0–18) | 76 | 40 | 26 | 26 |
| CRP mg/L (<5) | 48.7 | 6.8 | 6.8 | 6.8 |
uptake in the distal ends of the femurs and the tibias which may be associated with skeletal involvement of the ECD. However the patient didn’t have any bone pain. Approximately half of the cases of ECD present with extraskeletal manifestations. The most common cardiovascular manifestation is periaortic fibrosis that appears as a coated aorta. In our patient, there was dense infiltration surrounding the abdominal aorta. Retropertitoneal involvement is also a common feature of ECD. In our case, there was hairy kidney appearance due to symmetric and bilateral infiltration of the perirenal space and creatinin level was elevated and hydronephrosis was present. These were highly suggestive of the diagnosis. Testis infiltration is an unusual localization of ECD. A review of the literature revealed six cases of testis involvement. Two of them were reported in a series of 42 patients with ECD. Our case was with testis and pituitary involvement. He was diagnosed with only testis biopsy. ECD can also involve the central nervous system. Our patient was initially presented with diabetes insipidus with thickening of the pituitary stalk, but we didn’t obtain tissue specimen from the pituitary gland.

Because of the rarity of this disease, there is no consensus on the standard treatment for ECD. Currently, IFN-alpha is preferred for the treatment and associated with improved survival. Treatment should be continued indefinitely if tolerated. Treatment for ECD is now moving toward targeted therapy mostly due to the high percentage of proven BRAF V600E-positive cases. In our case, the BRAF mutation wasn’t detected in heavily infiltrated testis tissue. In the recent report of Ozkaya et al. they also didn’t find BRAF mutation however they detected MAP2K1 mutation in the testis of one patient. IFN-alpha was started to our patient. CRP and ESR levels decreased but testosterone level didn’t change.

Conclusion

The wide clinical spectrum and poor knowledge about this rare disease make its diagnosis difficult, therefore clinical suspicion is an important factor in its diagnosis. Due to raising awareness of ECD, the number of new diagnoses is increasing dramatically. It is necessary to perform biopsies and immunohistochemical staining for a correct diagnosis. In BRAF mutation-harboring forms of ECD vemurafenib therapy can be used. Further research on large patient groups with long-term follow-up is needed to better understand and treat this disease.

Appendix A. Supplementary data

Supplementary data related to this article can be found at https://doi.org/10.1016/j.eucr.2018.02.007.

Statement of ethics

Written consent of the patient was obtained for publication of this case report.

Declaration of conflicting interests

The authors declared that they have no competing interests.

References

1. Emile JF, Abla O, Fraitag S, et al. Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages. Blood. 2016;127:2672–2681.
2. Chester W. Uber Lipoidgranulomatose Virchows Arch Pathol Anat. vol 279. 1930:561–602.
3. Diomand EL, Dagna L, Hyman DM, et al. Consensus guidelines for diagnosis and clinical management of erdheim-Chester disease. Blood. 2014;124:483–492.
4. Haroche J, Cohen-Aubart F, Charlotte F, et al. The histiocytosis Erdheim-Chester disease is an inflammatory myeloid neoplasm. Expert Rev Clin Immunol. 2015;21:1–10.
5. Ozkaya Neval, Rosenblum Marc K, Durham Benjamin H, et al. The histopathology of Erdheim-Chester disease: a comprehensive review of a molecularly characterized cohort. Mod Pathol. 2017;1:1–17.